SG Americas Securities LLC Buys 62,233 Shares of LivaNova PLC $LIVN

SG Americas Securities LLC lifted its position in LivaNova PLC (NASDAQ:LIVN) by 256.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,490 shares of the company’s stock after acquiring an additional 62,233 shares during the quarter. SG Americas Securities LLC owned approximately 0.16% of LivaNova worth $5,497,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in LIVN. Diversified Trust Co lifted its position in shares of LivaNova by 12.3% during the first quarter. Diversified Trust Co now owns 21,028 shares of the company’s stock valued at $1,337,000 after purchasing an additional 2,303 shares in the last quarter. Hsbc Holdings PLC grew its position in LivaNova by 260.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,301 shares of the company’s stock worth $1,255,000 after purchasing an additional 14,671 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in LivaNova in the 4th quarter valued at about $302,000. Pacer Advisors Inc. lifted its position in shares of LivaNova by 131.7% during the 4th quarter. Pacer Advisors Inc. now owns 16,661 shares of the company’s stock worth $1,025,000 after buying an additional 9,471 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of LivaNova by 4.5% in the 4th quarter. Invesco Ltd. now owns 1,091,086 shares of the company’s stock worth $67,135,000 after buying an additional 47,323 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity

In related news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares in the company, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.35% of the stock is currently owned by company insiders.

LivaNova Stock Performance

Shares of LIVN opened at $83.38 on Monday. The firm has a market cap of $4.58 billion, a PE ratio of 42.76 and a beta of 0.88. The stock’s fifty day moving average price is $72.20 and its two-hundred day moving average price is $66.95. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $83.98.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the prior year, the company earned $0.88 EPS. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities research analysts forecast that LivaNova PLC will post 3.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LIVN shares. KeyCorp increased their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Monday, June 22nd. Mizuho upped their price objective on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Barclays raised their target price on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Weiss Ratings upgraded LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Finally, Robert W. Baird cut their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $80.75.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.